Co-Diagnostics (CODX) announced that it has signed a strategic Memorandum of Understanding with a regional manufacturing and distribution company located in the Kingdom of Saudi Arabia, to explore a joint venture that would be granted a license to develop, manufacture, and sell Co-Dx intellectual property throughout the Middle East and North Africa, including the company’s upcoming Co-Dx PCR point-of-care platform. According to the MOU, the KSA partner company in the JV would contribute local operational support, access to infrastructure, personnel, regulatory expertise, and other mission-critical resources in furtherance of the JV’s objectives across MENA countries, similar to the company’s operations in India through its Indian JV, CoSara Diagnostics Pvt Ltd.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics performs in silico analysis of primers sets for chikungunya virus
- Co-Diagnostics Earnings Call: Progress Amid Financial Struggles
- Co-Diagnostics Faces Financial Challenges and Regulatory Hurdles Amidst Hold Rating
- Co-Diagnostics Reports Q2 2025 Financial Results
- Is CODX a Buy, Before Earnings?